Collegium pays Grünenthal $17M to settle Nucynta ER patent suit and terminate 2015 license

COLLEGIUM PHARMACEUTICAL, INC

Collegium paid Grünenthal $17,000,000 to resolve the Nucynta Litigation, a patent suit Grünenthal filed in February 2026 in the U.S. District Court for New Jersey.
The October 15, 2026 Settlement Agreement terminates the 2015 Grünenthal License and the Consent Agreement in the Territory, discharging all royalty obligations.
Grünenthal assigned certain Nucynta Products patents to Collegium and filed a motion to dismiss the Nucynta Litigation.
The Consent Agreement otherwise continues in full force and effect; the report was signed by EVP and CFO Colleen Tupper on October 19, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.